Cancer is the second foremost reason for worldwide death, affecting every country of
the globe. However, 70% of cancer-related death was reported from low- and middle-income nations.
Delay in the detection and intervention of therapeutic agents in cancer patients also promoted
a cancer-related mortality index. Currently, numerous nanomedicines are under development for advancing
tumor diagnosis and therapeutic capability. Recently, liquid crystalline nanoparticles (LCNPs)
have emerged as an attractive drug delivery system for both intravenous and non-intravenous
applications. The widely explored LCNPs for cancer therapy include cubosomes and hexosomes.
They have significant advantages over other drug delivery system, which includes, high internal
surface area, unique solubilization properties and sustained release of entrapped drug molecules
and co-loading of imaging and therapeutic agents in a single system. In this review, we have briefly
discussed the advantages of LCNPs, preparation methods, and their multifunctional role in treating